Previous Study: TRIO030
Next Study: TRIO028

Studies & Results

TRIO029

A Phase 1, Open-Label Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

View FDA Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org